Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...

Novo Nordisk has reported 22% weight loss in people who received weekly amycretin injections for 36 weeks, triggering an 11% ...

Ozempic, Wegovy, Zepbound and other drugs often used for weight loss can help lower the risk of a wide range of health conditions, according to a new study. But the drugs also pose certain risks. Kyle ...

A new generation of obesity drugs – such as Novo Nordisk A/S’ Wegovy and Eli Lilly and Company’s Zepbound – is changing the perception of obesity as a multifaceted illness that requires ...

Lexaria Bioscience Corp., a global innovator in drug delivery platforms, has announced partial final results showcasing the ...

the company has launched a single-dose 2.5 mg and 5 mg Zepbound vials in the U.S. exclusively through LillyDirect for less than half the list price of other incretin medicines for obesity.

On the basis of the clinical trial data, patients on Zepbound (tirzepatide) 5mg weekly lost 16.1 kg (35.5 lb) on average after 72 weeks. For Zepbound’s 10mg weekly dose, the average weight loss ...

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.